<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01474330</url>
  </required_header>
  <id_info>
    <org_study_id>CC-4047-CP-006</org_study_id>
    <nct_id>NCT01474330</nct_id>
  </id_info>
  <brief_title>A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) Following Multiple Daily Doses in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, tolerability, and pharmacokinetics of pomalidomide administered
      orally once a day for 5 days, at daily doses of 0.5 mg, 1 mg, or 2 mg.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>28 days after last dose</time_frame>
    <description>Number of participants with adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the plasma concentration-time curve</measure>
    <time_frame>72 hours after last dose</time_frame>
    <description>area under the plasma concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>time to maximum observed plasma concentration</measure>
    <time_frame>72 hours after last dose</time_frame>
    <description>time to maximum observed plasma concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>maximum observed plasma concentration</measure>
    <time_frame>72 hours after last dose</time_frame>
    <description>maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>terminal elimination half-life</measure>
    <time_frame>72 hours after last dose</time_frame>
    <description>terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apparent total plasma clearance</measure>
    <time_frame>72 hours after last dose</time_frame>
    <description>apparent total plasma clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apparent total volume of distribution, and accumulation ratio</measure>
    <time_frame>72 hours after last dose</time_frame>
    <description>apparent total volume of distribution, and accumulation ratio</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>0.5-mg Pomalidomide or placebo (Cohort A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 0.5-mg pomalidomide capsule or matching placebo administered once daily for 5 days under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1-mg Pomalidomide or placebo (Cohort B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm may be initiated pending a safety review of Cohort A. A single 1-mg pomalidomide capsule or matching placebo administered once daily for 5 days under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-mg Pomalidomide or placebo (Cohort C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm may be initiated pending a safety review of Cohort B. A single 2-mg pomalidomide capsule or matching placebo administered once daily for 5 days under fasted conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>0.5-mg, 1-mg, or 2-mg capsule administered once daily for 5 days under fasted conditions</description>
    <arm_group_label>0.5-mg Pomalidomide or placebo (Cohort A)</arm_group_label>
    <arm_group_label>1-mg Pomalidomide or placebo (Cohort B)</arm_group_label>
    <arm_group_label>2-mg Pomalidomide or placebo (Cohort C)</arm_group_label>
    <other_name>CC-4047</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule</description>
    <arm_group_label>0.5-mg Pomalidomide or placebo (Cohort A)</arm_group_label>
    <arm_group_label>1-mg Pomalidomide or placebo (Cohort B)</arm_group_label>
    <arm_group_label>2-mg Pomalidomide or placebo (Cohort C)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy male subjects of any ethnic origin between ages of 18 and 55 with a body mass index
        between 19 and 30

        Exclusion Criteria:

          1. Any condition, including the presence of laboratory abnormalities, or psychiatric
             illness, that would prevent the subject from signing the Informed Consent Document
             (ICD), places the subject at unacceptable risk if he were to participate in the study,
             or confounds the ability to interpret data from the study.

          2. Presence of any surgical or medical conditions possibly affecting drug absorption,
             distribution, metabolism, and excretion, or plans to have elective or medical
             procedures during the conduct of the trial.

          3. Exposure to an investigational drug (new chemical entity) within 30 days prior to the
             first dose administration or 5 half-lives of that investigational drug, if known
             (whichever is longer).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Palmisano</last_name>
    <role>Study Director</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Phase I Clinic</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2011</study_first_submitted>
  <study_first_submitted_qc>November 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2011</study_first_posted>
  <last_update_submitted>March 25, 2016</last_update_submitted>
  <last_update_submitted_qc>March 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pomalidomide</keyword>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

